STAGE IVA PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVA PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo for tough prostate cancer falls short in early trial
Disease control TerminatedThis study tested a combination of two drugs, apalutamide and abiraterone acetate, plus prednisone, in men with castration-resistant prostate cancer that had spread. The goal was to see if the combo could slow cancer growth. Only 7 people enrolled before the study was stopped ear…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:32 UTC
-
Prostate cancer drug study halted early – what researchers learned
Disease control TerminatedThis study tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to bone. The goal was to see if the drug could slow the cancer and to study changes in blood and bone marrow. The study was stopped early, so results are limited.
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo aims to outsmart drug resistance in advanced prostate cancer
Disease control TerminatedThis early-phase trial tested a combination of two drugs—decitabine/cedazuridine and enzalutamide—in 8 men with metastatic castration-resistant prostate cancer that had stopped responding to standard treatment. The goal was to find a safe dose and see if the combination could rev…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Radioactive treatment aims to ease bone pain in prostate cancer patients
Symptom relief TerminatedThis study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that has spread to the bones. Only one person took part before the study was stopped early. The goal was to measure pain relief over several weeks.
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC